Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD + acute myeloid leukemia

References

• De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang F, Chen X, et al. Mutation profiling of 16 candidate genes in de novo acute myeloid leukemia patients. Front Med. 2019;13(2):229–237.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology Am Soc Hematol Educ Program. 2016;2016(1):348–355.
   PubMedGoogle Scholar
• Wang X, Huang S, Chen JL. Understanding of leukemic stem cells and their clinical implications. Mol Cancer. 2017;16(1):2.
   PubMedGoogle Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61.
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Murugaiyan G, Farez MF, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107(48):20768–20773.
   PubMed Web of Science ®Google Scholar
• Shinde R, Hezaveh K, Halaby MJ, et al. Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans. Nat Immunol. 2018;19(6):571–582.
   PubMed Web of Science ®Google Scholar
• Xue P, Fu J, Zhou Y. The Aryl Hydrocarbon Receptor and Tumor Immunity. Front Immunol. 2018;9:286.
   PubMed Web of Science ®Google Scholar
• Kolluri SK, Jin UH, Safe S. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as an anti-cancer drug target. Arch Toxicol. 2017;91(7):2497–2513.
   PubMed Web of Science ®Google Scholar
• Yin J, Sheng B, Han B, et al. The AhR is involved in the regulation of LoVo cell proliferation through cell cycle-associated proteins. Cell Biol Int. 2016;40(5):560–568.
   PubMed Web of Science ®Google Scholar
• O’Donnell EF, Koch DC, Bisson WH, et al. The aryl hydrocarbon receptor mediates raloxifene-induced apoptosis in estrogen receptor-negative hepatoma and breast cancer cells. Cell Death Dis. 2014;5:e1038.
   PubMed Web of Science ®Google Scholar
• Fukasawa K, Kagaya S, Maruyama S, et al. A novel compound, NK150460, exhibits selective antitumor activity against breast cancer cell lines through activation of aryl hydrocarbon receptor. Mol Cancer Ther. 2015;14(2):343–354.
   PubMed Web of Science ®Google Scholar
• Becker A, Klapczynski A, Kuch N, et al. Gene expression profiling reveals aryl hydrocarbon receptor as a possible target for photobiomodulation when using blue light. Sci Rep. 2016;6:33847.
   PubMed Web of Science ®Google Scholar
• Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997):1345–1348.
   PubMed Web of Science ®Google Scholar
• Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19(1):138–152. Epub 2011/01/22.
   PubMed Web of Science ®Google Scholar
• van Lochem EG, van der Velden VH, Wind HK, et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004;60(1):1–13.
   PubMedGoogle Scholar
• Kraft SC, Rimpila JJ, Fitch FW, et al. Immunohistochemical studies of the colon in ulcerative colitis. Arch Pathol. 1966;82(4):369–378.
   PubMedGoogle Scholar
• Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617–1628.
   PubMed Web of Science ®Google Scholar
• Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. Blood. 2017;129(2):257–260.
   PubMed Web of Science ®Google Scholar
• Takahashi S. Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications. J Hematol Oncol. 2011;4:13.
   PubMed Web of Science ®Google Scholar
• Larigot L, Juricek L, Dairou J, et al. AhR signaling pathways and regulatory functions. Biochim Open. 2018;7:1–9.
   PubMedGoogle Scholar
• Syed DN, Mukhtar H. FICZ: A Messenger of Light in Human Skin. J Invest Dermatol. 2015;135(6):1478–1481.
   PubMed Web of Science ®Google Scholar
• Krishnan S, Ding Y, Saedi N, et al. Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Rep. 2018;23(4):1099–1111.
   PubMed Web of Science ®Google Scholar
• Rannug A, Rannug U. The tryptophan derivative 6-formylindolo[3,2-b]carbazole, FICZ, a dynamic mediator of endogenous aryl hydrocarbon receptor signaling, balances cell growth and differentiation. Crit Rev Toxicol. 2018;48(7):555–574.
   PubMed Web of Science ®Google Scholar
• Bunaciu RP, Yen A. 6-Formylindolo (3,2-b)carbazole (FICZ) enhances retinoic acid (RA)-induced differentiation of HL-60 myeloblastic leukemia cells. Mol Cancer. 2013;12:39.
   PubMed Web of Science ®Google Scholar
• Gentil M, Hugues P, Desterke C, et al. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML). PLoS One. 2018;13(8):e0200923.
   PubMed Web of Science ®Google Scholar
• Gaballa S, Saliba R, Oran B, et al. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017;92(4):331–337.
   PubMed Web of Science ®Google Scholar
• Grafone T, Palmisano M, Nicci C, et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment. Oncol Rev. 2012;6(1):e8.
   PubMedGoogle Scholar
• Frohling S, Scholl C, Levine RL, et al. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell. 2007;12(6):501–513.
   PubMed Web of Science ®Google Scholar
• Staudt D, Murray HC, McLachlan T, et al. Targeting oncogenic signaling in mutant FLT3 acute myeloid leukemia: the path to least resistance. Int J Mol Sci. 2018;19(10).
   PubMed Web of Science ®Google Scholar
• Siveen KS, Uddin S, Mohammad RM. Targeting acute myeloid leukemia stem cell signaling by natural products. Mol Cancer. 2017;16(1):13.
   PubMedGoogle Scholar